AnaptysBio falls after data abstract on Lilly’s peresolimab

According to a report in the American College of Rheumatology, Eli Lilly’s (LLY) peresolimab was superior to the placebo at week 12 for several key endpoints in patients with rheumatoid arthritis, but the drug’s efficacy was not differentiated from existing treatment options. “In context of observed efficacy combined with the number of reported malignancies and possible MACEs through week 60, the study was stopped based on the non-favorable benefit/risk profile for peresolimab in treating RA patients,” the journal states. Shares of AnaptysBio (ANAB), which is developing a similar PD-1 agonist, are down 4% to $19.39 in midday trading.